Comparison of methods for proliferative index analysis for grading pancreatic well-differentiated neuroendocrine tumors

American Journal of Clinical Pathology

Volumn 137, Issue 4, 2012, Pages 576-582

  Goodell, Pamela P ^a   Krasinskas, Alyssa M ^a   Davison, Jon M ^a   Hartman, Douglas J ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Digital image analysis; Grading neuroendocrine tumors; Ki 67; Neuroendocrine tumor; Pancreatic neuroendocrine tumor; Proliferative index

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMAGING SYSTEM; MALE; METASTASIS; MITOSIS INDEX; PANCREATIC NEUROENDOCRINE TUMOR; PREDICTIVE VALUE; PRIORITY JOURNAL; PROLIFERATIVE INDEX; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION; TUMOR GROWTH; CELL COUNT; CELL PROLIFERATION; COMPARATIVE STUDY; METHODOLOGY; MIDDLE AGED; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PATHOLOGY; PILOT STUDY; PROGNOSIS;

ADULT; AGED; CELL COUNT; CELL PROLIFERATION; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; MITOTIC INDEX; NEOPLASM GRADING; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS; PILOT PROJECTS; PROGNOSIS;

EID: 84860592788     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP92UCXPJMMSDU     Document Type: Article

References (25)

1. Klimstra DS, Capella C, Arnold R. Neuroendocrine neoplasms of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, et al., eds. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon, France: IARC Press; 2010:322-326.
2. Rindi G, Arnold R, Bosman FT. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, et al. eds. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon, France: IARC Press; 2010:13-14.
3. Pelosi G, Bresaola E, Bogina G, et al.Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol. 1996;27:1124-1134. (Pubitemid 26374929)
4. Ekeblad S, Skogseid B, Dunder K, et al.Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008;14:7798-7803.
5. Deshpande V, Fernandez-del Castillo C, Muzikansky A, et al.Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors. Am J Surg Pathol. 2004;28:1145-1153. (Pubitemid 39121608)
6. Zhang L, Lohse CM, Dao LN, et al.Proposed histopathologic grading system derived from a study of KIT and CK19 expression in pancreatic endocrine neoplasm. Hum Pathol. 2011;42:324-331.
7. Rindi G, Kloppel G, Alhman H, et al.TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449:395-401. (Pubitemid 44451313)
8. Ferrone CR, Tang LH, Tomlinson J, et al.Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol. 2007;25:5609-5615.
9. Hochwald SN, Zee S, Conlon KC, et al.Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol. 2002;20:2633-2642. (Pubitemid 34575635)
10. Edge SB, Byrd DR, Compton CC, et al., eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2009.
11. Scarpa A, Mantovani W, Capelli P, et al.Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol. 2010;23:824-833.
12. Pomianowska E, Gladhaug IP, Grzyb K, et al.Survival following resection of pancreatic endocrine tumors: importance of R-status and the WHO and TNM classification systems. Scand J Gastroenterol. 2010;45:971-979.
13. Verbeke CS. Endocrine tumours of the pancreas. Histopathology. 2010;56:669-682.
14. Lejeune M, Jaen J, Pons L, et al.Quantification of diverse subcellular immunohistochemical markers with clinicobiological relevancies: validation of a new computer-assisted image analysis procedure. J Anat. 2008;212:868-878. (Pubitemid 351772667)
15. Minot DM, Kipp BR, Root RM, et al.Automated Cellular Imaging System III for assessing HER2 status in breast cancer specimens: development of a standardized scoring method that correlates with FISH. Am J Clin Pathol. 2009;132:133-138.
16. Wang S, Saboorian MH, Frenkel EP, et al.Assessment of HER-2/neu status in breast cancer: Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol. 2001;116:495-503. (Pubitemid 34450283)
17. Dhall D, Frishberg DP, Galliano G, et al.Interobserver variability in assessing Ki-67 proliferative index in gastrointestinal well-differentiated neuroendocrine neoplasms. Mod Pathol. 2009;22:116A. Abstract 515.
18. Washington K, Tang LH, Berlin J, et al.Protocol for the Examination of Specimens From Patients With Carcinoma of the Endocrine Pancreas. Northfield, IL: College of American Pathologists; 2011.
19. Raymond E, Dahan L, Raoul JL, et al.Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501-513.
20. Strosberg JR, Cheema A, Weber J, et al.Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors [published online ahead of print June 27, 2011]. J Clin Oncol. 2011;29:3044-3049.
21. Strimpakos AS, Syrigos KN, Saif MW. Pancreatic neuroendocrine tumors: role of novel agents: highlights from the "2011 ASCO Gastrointestinal Cancers Symposium," San Francisco, CA, USA. January 20-22, 2011. JOP. 2011;12:117-119.
22. Yao JC, Shah MH, Ito T, et al.Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:514-523.
23. Klimstra DS, Modlin IR, Adsay NV, et al.Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol. 2010;34:300-313.
24. Ong CW, Kim LG, Kong HH, et al.Computer-assisted pathological immunohistochemistry scoring is more time-effective than conventional scoring, but provides no analytical advantage. Histopathology. 2010;56:523-529.
25. Couvelard A, Deschamps L, Ravaud P, et al.Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors. Mod Pathol. 2009;22:273-281.